These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 32660394)

  • 1. An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma.
    Rolla G; Heffler E; Pizzimenti S; Michils A; Malinovschi A
    Curr Med Chem; 2020; 27(42):7159-7167. PubMed ID: 32660394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological treatments for severe asthma: A major advance in asthma care.
    Busse WW
    Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies for the treatment of refractory asthma.
    Hambly N; Nair P
    Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
    Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
    Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision care in the treatment of pediatric asthma.
    Mahmood L; Keskin S; Jefferson AA
    Curr Opin Pediatr; 2024 Jun; 36(3):304-309. PubMed ID: 38411592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy.
    Kayser MZ; Suhling H; Fuge J; Hinze CA; Drick N; Kneidinger N; Behr J; Taube C; Welte T; Haasler I; Milger K
    BMC Pulm Med; 2024 Mar; 24(1):149. PubMed ID: 38515071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
    Chan R; RuiWen Kuo C; Lipworth B
    J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choice of biologics in asthma endotypes.
    Wangberg H; Woessner K
    Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab for the treatment of asthma.
    Santini G; Mores N; Malerba M; Mondino C; Anzivino R; Macis G; Montuschi P
    Expert Opin Investig Drugs; 2017 Mar; 26(3):357-366. PubMed ID: 28085503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients.
    Pasha MA; Jourd'heuil D; Jourd'heuil F; Mahon L; Romero F; Feustel PJ; Evans M; Smith T; Mitchell J; Gendapodi P; Demeyere-Coursey KC; Townley RG
    Allergy Asthma Proc; 2014; 35(3):241-9. PubMed ID: 24801467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological treatments for severe asthma: where do we stand?
    Busse WW
    Curr Opin Allergy Clin Immunol; 2018 Dec; 18(6):509-518. PubMed ID: 30299397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma.
    Gottlow M; Svensson DJ; Lipkovich I; Huhn M; Bowen K; Wessman P; Colice G
    BMC Pulm Med; 2019 Jul; 19(1):129. PubMed ID: 31315668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.
    Porsbjerg CM; Townend J; Bergeron C; Christoff GC; Katsoulotos GP; Larenas-Linnemann D; Tran TN; Al-Lehebi R; Bosnic-Anticevich SZ; Busby J; Hew M; Kostikas K; Papadopoulos NG; Pfeffer PE; Popov TA; Rhee CK; Sadatsafavi M; Tsai MJ; Ulrik CS; Al-Ahmad M; Altraja A; Beastall A; Bulathsinhala L; Carter V; Cosio BG; Fletton K; Hansen S; Heaney LG; Hubbard RB; Kuna P; Murray RB; Nagano T; Pini L; Cano Rosales DJ; Schleich F; Wechsler ME; Amaral R; Bourdin A; Brusselle GG; Chen W; Chung LP; Denton E; Fonseca JA; Hoyte F; Jackson DJ; Katial R; Kirenga BJ; Koh MS; Ławkiedraj A; Lehtimäki L; Liew MF; Mahboub B; Martin N; Menzies-Gow AN; Pang PH; Papaioannou AI; Patel PH; Perez-De-Llano L; Peters MJ; Ricciardi L; Rodríguez-Cáceres B; Solarte I; Tay TR; Torres-Duque CA; Wang E; Zappa M; Abisheganaden J; Assing KD; Costello RW; Gibson PG; Heffler E; Máspero J; Nicola S; Perng Steve DW; Puggioni F; Salvi S; Sheu CC; Sirena C; Taillé C; Tan TL; Bjermer L; Canonica GW; Iwanaga T; Jiménez-Maldonado L; Taube C; Brussino L; Price DB
    Front Immunol; 2024; 15():1361891. PubMed ID: 38711495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit.
    Pepper AN; Hanania NA; Humbert M; Casale TB
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1081-1088. PubMed ID: 33685606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of the Utility and Cost Effectiveness of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management.
    Arnold RJ; Massanari M; Lee TA; Brooks E
    Manag Care; 2018 Jul; 27(7):34-41. PubMed ID: 29989900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
    Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
    Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.
    Charles D; Shanley J; Temple SN; Rattu A; Khaleva E; Roberts G
    Clin Exp Allergy; 2022 May; 52(5):616-627. PubMed ID: 35174566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exhaled nitric oxide for monitoring childhood asthma inflammation compared to sputum analysis, serum interleukins and pulmonary function.
    Paro-Heitor ML; Bussamra MH; Saraiva-Romanholo BM; Martins MA; Okay TS; Rodrigues JC
    Pediatr Pulmonol; 2008 Feb; 43(2):134-41. PubMed ID: 18085692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma.
    Menigoz C; Dirou S; Chambellan A; Hassoun D; Moui A; Magnan A; Blanc FX
    J Asthma; 2023 Jun; 60(6):1162-1170. PubMed ID: 36301080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of exhaled nitric oxide in the diagnosis and management of asthma.
    Majid H; Kao C
    Curr Opin Pulm Med; 2010 Jan; 16(1):42-7. PubMed ID: 19797954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.